Clinical improvement · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in clinical improvement compared with beclometasone (low certainty).
1 finding from 1 review
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus may leads to higher clinical improvement compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes clinical improvement compared with ciclosporin (very low certainty).
1 finding from 1 review
Clinical improvement · patients with induction of remission in ulcerative colitis
It is very uncertain whether LMWH + standard therapy changes clinical improvement compared with standard therapy (very low certainty).
1 finding from 1 review
Clinical improvement · patients with induction of remission in ulcerative colitis
It is very uncertain whether UFH changes clinical improvement compared with corticosteroids (very low certainty).
1 finding from 1 review
Clinical improvement · patients with induction of remission in ulcerative colitis
Type I Interferons showed no clear difference in clinical improvement compared with placebo (moderate certainty).
1 finding from 1 review
Clinical improvement · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in clinical improvement compared with placebo (moderate certainty).
1 finding from 1 review
Clinical improvement · Adult patients with active ulcerative colitis
Budesonide showed no clear difference in clinical improvement compared with mesalamine (moderate certainty).
1 finding from 1 review
Clinical improvement · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in clinical improvement compared with entocort EC 9mg (moderate certainty).
1 finding from 1 review
Clinical improvement · Adult patients with active ulcerative colitis
Budesonide MMX® 6 mg showed no clear difference in clinical improvement compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement (Mayo score) (9 weeks) · Patients with active mild to moderate ulcerative colitis
It is very uncertain whether inulin and oligofructose 15 g changes clinical improvement (Mayo score) (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
1 finding from 1 review
Disease improvement (based on clinical scores) · people with active UC
Probiotics may leads to higher disease improvement (based on clinical scores) compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement (Lichtiger index) (4 weeks) · Patients with active mild to moderate ulcerative colitis
1 finding from 1 review
Failure to induce global or clinical improvement · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in failure to induce global or clinical improvement compared with conventional dosing (moderate certainty).
1 finding from 1 review
Failure to induce global or clinical improvement · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower failure to induce global or clinical improvement compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce global or clinical improvement · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in failure to induce global or clinical improvement compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
Failure to induce global or clinical improvement · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in failure to induce global or clinical improvement compared with SASP (high certainty).
1 finding from 1 review
Clinical improvement (partial Mayo score) (60 days) · people with histologically confirmed diagnosis of ulcerative colitis in remission
1 finding from 1 review